Page 11 - Pharma Stocks

Vijaya Diagnostic hits new high, stock up 65% in 4 months on strong Q2 nos

In Q2 the company delivered impressive 31.8% YoY revenue growth, of which 23.0% was organic, driven primarily by volume, with contributions coming from both its existing and newly launched centres.

Akums Drugs tanks 10%, falls below issue price on weak Q2 earnings

In two days, the stock price of Akums Drugs has declined 19% to Rs 645.30 and fallen below its issue price of Rs 679 per share.

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Gland Pharma soars 13% on better than expected Q2 performance

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Piramal Pharma stock hits new, soars 25% in 6 days on strong Q2 results

Over the long term, the management remains committed to achieving the company's financial goals of $2 billion revenue with 25 per cent EBITDA margin and 1x net debt / EBITDA by FY30.

This pharma stock has zoomed over 380% in Samvat 2080; trades at 8-yr high

Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.

Jagsonpal Pharma up 7% as co to consider Q2 results, stock-split on Oct 23

The uptick in Jagsonpal Pharma share price came after the company announced that its board of directors will meet on October 23 to consider Q2 and H1FY25 results and proposal for stock-split

Wockhardt gains 4% on filing for DCGI's approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Lyka Labs shares rally 7% on CDSCO nod for diabetic neuropathy pain drug

Lyka Labs shares rose as the company announced that it has received the CDSCO approval for manufacturing & marketing of of Pregabalin Gel 8% w/w for use in patients with Diabetic Neuropathic Pain.

Here's why Natco Pharma share price gained over 4% on October 7; details

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details

Shilpa Medicare share price surged after the company said that its arm, Shilpa Pharma Lifesciences, has received certificate of suitability (CEP) from EDQM for API, Desmopressin

Alembic Pharma share price gains 5% after USFDA okays seizures drug

Alembic Pharma share price surged after the United States Food and Drug Administration (USFDA) gave final approval for Lamotrigine ExtendedRelease Tablets USP, 200 mg, 250 mg, and 300 mg.

What drove this pharmaceutical stock's 4% increase today? Find out here!

Alembic Pharma share price surged after the USFDA issued establishment inspection report (EIR) for the inspection carried out at the company's Oral Solid Formulation Facility (F-I).

Lupin share falls over 2% as USFDA issues 3 observations for Pithampur unit

Lupin share price fell after the United States Food and Drug Administration (USFDA) issued 3 observations for its Pithampur Unit-1, based in Madhya Pradesh.

Sun Pharma gains 3%; hits new high on UBS 'Buy' rating, sees more upside

UBS has a target price of Rs 2,450 on Sun Pharma and expects it to record the highest growth in the near-term and the medium-term via a ramp-up of the specialty drug pipelline.

SeQuent Scientific jumps 18% after announcing merger with Viyash Life

The company said the proposed merger is expected to be Ebitda margin accretive and deleverage SeQuent's balance sheet.fle

UBS fears slowdown in India, US pharma markets; gives 'Sell' on 4 stocks

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

Nifty Pharma, FMCG indices range-bound; Check support and other levels here

The Nifty Pharma Index is currently trading in a defined range between 23,700 and 22,700. This suggests that the market is experiencing indecision, with neither buyers nor sellers dominating.

Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others

Lupin is preparing the launch of PredForte, having a market of $200 million with 180 days competitive generic therapy (CGT) exclusivity in the near term